glucocorticoids

Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis
Yuchuan Ding, Baozhen Huang, Yuan Wang, Jun Hou, Ying Chi, Zhixuan Zhou, Jianguo Li

Annals of the Rheumatic Diseases Oct 2020, annrheumdis-2020-218582; DOI: 10.1136/annrheumdis-2020-218582
Response to: ‘Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’’ by Jeny et al
Andrea Hermina Györfi, Georg Schett, Jörg H W Distler

Annals of the Rheumatic Diseases Oct 2020, annrheumdis-2020-218983; DOI: 10.1136/annrheumdis-2020-218983
Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): what does the future hold?
Murugan Sudhakar, Pandiarajan Vignesh

Annals of the Rheumatic Diseases Sep 2020, annrheumdis-2020-218738; DOI: 10.1136/annrheumdis-2020-218738
Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases
Alessandro Giollo, Eugenia Bertoldo, Giovanni Adami, Adam J Cybulski, Angelo Fassio, Giovanni Orsolini, Luca Idolazzi, Davide Gatti, Ombretta viapiana, Maurizio Rossini

Annals of the Rheumatic Diseases Sep 2020, annrheumdis-2020-218845; DOI: 10.1136/annrheumdis-2020-218845
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al
Kimme L Hyrich, Milena Gianfrancesco, Pedro M Machado, Jinoos Yazdany, Philip C Robinson

Annals of the Rheumatic Diseases Sep 2020, annrheumdis-2020-218910; DOI: 10.1136/annrheumdis-2020-218910
Management of immune checkpoint inhibitor-induced polymyalgia rheumatica
Kornelis S M van der Geest, Maria Sandovici, Abraham Rutgers, T Jeroen N Hiltermann, Sjoukje F Oosting, Riemer H J A Slart, Elisabeth Brouwer

Annals of the Rheumatic Diseases Sep 2020, annrheumdis-2020-218276; DOI: 10.1136/annrheumdis-2020-218276
Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al’ by Buckley
Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti

Annals of the Rheumatic Diseases Sep 2020, annrheumdis-2020-218715; DOI: 10.1136/annrheumdis-2020-218715
High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab
Edoardo Conticini, Federico Franchi, David Bennett, Serafina Valente, Maria A Mazzei, Elena Bargagli, Luca Volterrani, Sabino Scolletta, Bruno Frediani

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218761; DOI: 10.1136/annrheumdis-2020-218761
Response to: ‘High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab’ by Conticini et al
Sofia Ramiro, Rémy Mostard, Robert BM Landewé

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218788; DOI: 10.1136/annrheumdis-2020-218788
To immunosuppress: whom, when and how? That is the question with COVID-19
Kevin L Winthrop, Xavier Mariette

Annals of the Rheumatic Diseases Sep 2020, 79 (9) 1129-1131; DOI: 10.1136/annrheumdis-2020-218694

Main menu

glucocorticoids

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

glucocorticoids

Pages